Vanda Pharmaceuticals (VNDA) announced that the U.S. District Court for the District of Delaware denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA (TEVA) and Apotex and Apotex and ordered that Vanda’s HETLIOZ patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex. Vanda intends to proceed with discovery in the case to continue pursuing its claims. Vanda will request relief from the Court that includes an order requiring the Defendants to discontinue marketing their generic versions of HETLIOZ until the expiration of the patent-in-suit and enjoining them from the commercial manufacture, use, import, offer for sale and/or sale of these products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Butler Hall urges Vanda Pharmaceuticals board to run full sales process
- Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
- Vanda Pharmaceuticals confirms receipt of takeover proposal from Future Pak
- Vanda Pharmaceuticals Considers Cycle Group’s Preliminary Interest
- Vanda Pharmaceuticals receives indication of interest for $8.00 per share